Pietų Afrika - anglų - South African Health Products Regulatory Authority (SAHPRA)

zydus healthcare (pty) ltd - tablet - see ingredients - each tablet contains etoricoxib 60,0 mg

Pietų Afrika - anglų - South African Health Products Regulatory Authority (SAHPRA)

zydus healthcare (pty) ltd - tablet - see ingredients - each tablet contains etoricoxib 90,0 mg

Pietų Afrika - anglų - South African Health Products Regulatory Authority (SAHPRA)

zydus healthcare (pty) ltd - tablet - see ingredients - each tablet contains etoricoxib 120,0 mg

Pietų Afrika - anglų - South African Health Products Regulatory Authority (SAHPRA)

zydus healthcare (pty) ltd - tablet - see ingredients - each tablet contains apixaban 5,0 mg

Pietų Afrika - anglų - South African Health Products Regulatory Authority (SAHPRA)

zydus healthcare (pty) ltd - tablet - see ingredients - each tablet contains apixaban 2,5 mg

Pietų Afrika - anglų - South African Health Products Regulatory Authority (SAHPRA)

zydus healthcare (pty) ltd - capsules - see ingredients - each capsule contains dutasteride 0,5 mg

Jungtinės Valstijos - anglų - NLM (National Library of Medicine)

zydus pharmaceuticals (usa) inc. - nortriptyline hydrochloride (unii: 00fn6ih15d) (nortriptyline - unii:bl03sy4lxb) - nortriptyline hydrochloride capsules are indicated for the relief of symptoms of depression. endogenous depressions are more likely to be alleviated than are other depressive states. the use of maois intended to treat psychiatric disorders with nortriptyline hydrochloride or within 14 days of stopping treatment with nortriptyline hydrochloride is contraindicated because of an increased risk of serotonin syndrome. the use of nortriptyline hydrochloride within 14 days of stopping an maoi intended to treat psychiatric disorders is also contraindicated (see warnings and dosage and administration ). starting nortriptyline hydrochloride in a patient who is being treated with maois such as linezolid or intravenous methylene blue is also contraindicated because of an increased risk of serotonin syndrome (see warnings and dosage and administration ). cross-sensitivity between nortriptyline hydrochloride and other dibenzazepines is a possibility. nortriptyline hydrochloride is contraindicated during the acute rec

Pietų Afrika - anglų - South African Health Products Regulatory Authority (SAHPRA)

zydus healthcare (pty) ltd - #n/a - not indicated - none

Pietų Afrika - anglų - South African Health Products Regulatory Authority (SAHPRA)

zydus healthcare (pty) ltd - #n/a - not indicated - none

Pietų Afrika - anglų - South African Health Products Regulatory Authority (SAHPRA)

zydus healthcare (pty) ltd - tablets - not indicated - each tablet contains telmisartan 40,0 mg